STK38L Recombinant Monoclonal Antibody

STK38L, also known as NDR2 (Nuclear Dbf2-related kinase 2), is a serine/threonine protein kinase that plays essential roles in cell cycle regulation, centrosome duplication, and apoptotic signaling pathways. As a member of the NDR kinase family, STK38L participates in the Hippo signaling pathway, which governs organ size control and tissue homeostasis. Dysregulation of this kinase has been implicated in various cellular processes relevant to cancer biology and developmental disorders, making it a compelling target for researchers investigating cell proliferation mechanisms and tumor suppression networks.

This recombinant monoclonal antibody against human STK38L offers the reproducibility and consistency that demanding experimental workflows require. Generated using recombinant technology and produced as a human IgG1 isotype from clone 9A4, this antibody provides sequence-defined specificity that eliminates the lot-to-lot variability often encountered with traditional hybridoma-derived reagents. The antibody was raised against recombinant human STK38L protein and purified by affinity chromatography, ensuring high purity for sensitive downstream applications.

Validation studies using flow cytometry demonstrate clear detection of STK38L in HT29 human colorectal adenocarcinoma cells. The overlay histogram shows distinct separation between the antibody signal and isotype control when cells were fixed, permeabilized, and stained at a 1:100 dilution, confirming reliable intracellular detection of the target protein. The antibody is validated for both ELISA and flow cytometry applications, with recommended dilutions of 1:50 to 1:200 for flow cytometric analysis.

This antibody serves researchers studying Hippo pathway signaling, cell cycle checkpoint mechanisms, and kinase-mediated regulation of cell growth and survival.